Brand positioning and sharpening communication on brand values and equity
Our brand equity of better patency and resistance to infections has been amply justified with a cost benefit analysis based on fewer interventions for graft patency issues, lower infections and the more important decrease in the number of amputations in peripheral arterial disease and critical limb ischemia.
Market Assessment
We plan to assess product awareness and the attitude and usage of Omniflow II among key vascular surgeons in the markets where our flagship biosynthetic product Omniflow II has been approved for sale. Thanks to the help of some of you, we are beginning to understand the market and the brand value of Omniflow II .. Read More
Connecting with Vascular Surgeons
Our medical and product expertise allows us to better understand the unmet clinical needs that could be more effectively met by Omniflow II than competitive synthetic grafts. This insight can be translated into new revenue opportunities for us.